Diffuse large B-cell lymphoma with TP53 mutation/deletion at initial treatment Lymphoma
Conditions
Interventions
Observation group:None
Sponsors
Department of Hematology, Fifth Medical Center of the PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed as diffuse large B-cell lymphoma (DLBCL) by histopathology and immunohistochemistry; 2. Newly diagnosed patients with TP53 mutation or deletion confirmed by genetic testing; 3. Expected survival time > 6 months; 4. Obtained informed consent from the patient or their authorized relative.
Exclusion criteria
Exclusion criteria: 1. Severe liver and kidney dysfunction, such as serum creatinine exceeding twice the normal upper limit, or transaminase exceeding three times the normal upper limit. 2. Allergic to any component of selinexor or any drug in the R-DA-EPOCH regimen. 3. Have severe heart diseases, such as NYHA cardiac function classification at grade III - IV. 4. Patients who cannot tolerate chemotherapy, such as an ECOG performance status score greater than 2 points.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, OS;Progression-free survival, PFS; | — |
Countries
China
Contacts
Public ContactWenrong Huang
Fifth Medical Center of the PLA General Hospital
Outcome results
None listed